(Q33957451)

30 July 2017

1 reference

title

Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin (English)

1 reference

30 July 2017

Perfetti R

1

1 reference

30 July 2017

Ahmad A

series ordinal

2

1 reference

30 July 2017

publication date

1 August 2000

1 reference

Trends in Endocrinology and Metabolism

30 July 2017

published in

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

218-223

1 reference

ATP-sensitive K+ channels and insulin secretion: their role in health and disease.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

New and traditional treatment of glycemia in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Binding of hypoglycaemic sulphonylureas to an artificial phospholipid bilayer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Diabetic control with gliquidone--a short acting sulphonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

New treatments for patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Effects of the methyl esters of pyruvate, succinate and glutamate on the secretory response to meglitinide analogues in rat pancreatic islets

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Repaglinide versus glyburide: a one-year comparison trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

PHARMACOLOGY OF THE HYPOGLYCAEMIC SULPHONYLUREA GLIQUIDONE III. CONFORMATIONAL ANALYSIS

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Dissociation between the potency and reversibility of the insulinotropic action of two meglitinide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Mechanism of action of a new class of insulin secretagogues

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Effect of a novel hypoglycemic agent, KAD-1229 on glucose metabolism and fructose-2,6-bisphosphate content in isolated hepatocytes of normal rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Biphasic insulin-releasing effect of BTS 67 582 in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Glucose-lowering effect of BTS 67 582.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

BTS 67 582 stimulates insulin secretion from perifused rat pancreatic islets.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Evaluation of BTS 67 582, a novel antidiabetic agent, in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Insulin-releasing action of the novel antidiabetic agent BTS 67 582.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Effect of 1,1-dimethyl-2-[2-morpholinophenyl]guanidine fumarate on pancreatic islet function

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

Different Modes of Action of the Imidazoline Compound RX871024 in Pancreatic beta-Cells: Blocking of K+ Channels, Mobilization of Ca2+ from Endoplasmic Reticulum, and Interaction with Exocytotic Machinerya

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900269-1

7 January 2021

10.1016/S1043-2760(00)00269-1

Identifiers

DOI

1 reference

30 July 2017

1 reference